<DOC>
	<DOC>NCT01555619</DOC>
	<brief_summary>The purpose of this post approval study is to evaluate the acute and chronic performance of a Quadripolar CRT-D device system in a patient population indicated for cardiac resynchronization therapy.</brief_summary>
	<brief_title>Quadripolar Pacing Post Approval Study</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1. Approved indication per current ACC/AHA/HRS guidelines for implantation of a CRTD system for treatment of heart failure or life threatening ventricular tachyarrhythmia(s). 2. Participated in the Promote® Q CRTD and Quartet™ Left Ventricular Heart Lead Study (IDE study), or are receiving a new Quadripolar CRTD device system implant or are undergoing an upgrade from an existing ICD or pacemaker implant with no prior LV lead placement. 3. Have the ability to provide informed consent for study participation and be willing and able to comply with the prescribed followup tests and schedule of evaluations 1. Have a hypersensitivity to a single 1.0mg dose of dexamethasone sodium phosphate 2. Have a life expectancy of less than 5 years due to any condition 3. Be less than 18 years of age</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Left heart pacing lead</keyword>
	<keyword>Cardiac resynchronization therapy (CRT)</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Quadripolar pacing</keyword>
</DOC>